Connect with us

Industry

First novel food list published as CBD products face being pulled from shelves

Published

on

CBD oil
An initial list of validated CBD products has been published by the FSA

CBD companies are learning their fates as the Food Standards Agency begins to validate products permitted to remain on shelves in the UK.

All UK CBD companies were required to apply for novel food status by 31 March, under new regulations announced last year.

Under the new system, any company selling a CBD product that was on the market prior to 13 February needed to submit sufficient quality and safety data to the regulator for each product.

Companies are now being informed whether or not their products have met required standards from the FSA directly, and decisions are also being made available online via a public register.

The FSA has today confirmed that this initial list is only provisional, with a full register of authorised products not due to be completed until June 2021.

The list distinguishes between validated products and ‘on hold’ applications in instances where sufficient data has not yet been received but companies have set out ‘set out robust plans to complete the risk assessment’.

Products which have not submitted application should be withdrawn from the market with criminal prosecutions possible for company directors who do not comply.

Emily Miles, chief executive of the FSA, said: “This is about bringing the CBD industry into compliance with the law. Consumers need to be able to trust that these products are safe and are what they say they are.

“Companies were given until the end of March  to submit their applications for safety assessment. Those who haven’t done this should take their products off the market.

“Products on the list that have been linked to a validated or on hold application will now undergo a full safety assessment so that a final decision can be made.

“When complete, the list can be used by suppliers and retailers to confirm the status of particular products and to help local authorities inform their enforcement decisions.

“The FSA is not endorsing the sale of any of these products, regardless of whether they are on the list or not and inclusion on the list is no guarantee of eventual authorisation; that will be determined on the strength of evidence of safety submitted by the companies.”

At time of writing, only 23 products manufactured by three companies (Pureis, 4MP and CBDex) are currently validated and none added to the ‘on hold’ list as of yet.

Cannabis Health has approached the FSA for clarity over when the register will be completed.

Validation is only the ‘first step in the process’, according to the FSA, and is granted to products where sufficient lab data has been submitted to allow the agency to carry out further checks pending full authorisation.

As previously reported, there is no appeals process for companies whose products have been denied validation but the register will be updated weekly according to the FSA.

Industry

Isle of Man launches medical cannabis export sector

The Isle of Man is open for business to the medical cannabis industry.

Published

on

The move could 250 new jobs and generate £3 million a year for the island

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.

Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.

“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.

The Isle of Man wants to be a major player in Europe’s growing medical cannabis industry.

“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”

The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.

The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.

Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.

‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.

“What we now have will ensure that all stakeholders will be competent, crime free and capable of building a sector that is safe, trusted and efficient.

“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.

“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.

“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.

“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”

Continue Reading

Industry

Always Pure Organics announces major expansion to meet demand

Construction is underway on a new 10,000 square foot warehouse

Published

on

The APO team has grown from three people to over 50 staff members

Sponsored feature

Always Pure Organics has announced that construction is underway on its new 10,000 square foot warehouse as part of a major expansion, here they reveal all.

At Always Pure Organics, our mission is to accelerate the global access, acceptance and understanding of cannabinoids and their wide benefits.

We’re proud to take you ‘behind the scenes’, where you’ll meet our team and gain a further understanding of how we serve our clients and facilitate growth of the cannabinoid industry.

 

One of our latest projects involves expanding our Always Pure Organics facilities. Renovations began in early June and we are excited for the extra space that the expansion will afford our lab and operation teams.

Our CEO Gavin Ogilvie commented on the project: “We’re so proud of the growth we’ve achieved. In two and a half years the business has gone from three people working out of a bedroom to over 50 team members servicing 500 global clients.

“With this comes a responsibility to our customers and partners to continue to deliver the personal, quick and hands-on service that we have done historically. With the increasing demand placed on our operations and production teams this was becoming a mounting challenge. Therefore, we have invested heavily to overhaul and upsize our warehouse and clean rooms. This week we began the construction in our new 10,000 square foot warehouse.

“We want to offer the best products, with more variety, more quickly and with a better user experience than any of our competitors. This is just one step in achieving that.”

Always Pure Organics Specialist Manufacturer of Cannabis Based Products.

We offer the highest quality wholesale legal cannabis and cannabinoid products, as bulk ingredients, bulk products, white label, and bespoke formulations. This is coupled with regulatory and legal expertise and supported by delivery globally.

Our unique bespoke formulation products allow our customers to create their own product from scratch, whilst we provide the regulatory and product knowledge, as well as production of the product.

To find out more about how Always Pure Organics can support your business on its CBD journey visit alwayspureorganics.com or follow us on LinkedIn and YouTube.

Continue Reading

Industry

The UK cannabis veterans taking on the industry’s big beasts

AltoVerde wants to shake things up in the industry which it believes has gone from counter-culture to corporate.

Published

on

The company plans to open a 10,000+ square metre cultivation plant in Macedonia

Meet the UK executive and cannabis veteran, aiming to take on Europe and North America’s established industry titans.

Mitesh Makwana is the director of AltoVerde, a start up company looking to establish itself as one of the continent’s big players.

The race is on to put roots down in Europe with several countries expected to expand patient access in the coming years – and even open up adult use markets.

Huge companies from across the pond like Tilray, Aurora and Bedrocan have already got boots on the ground, buying up companies and starting operations in places like Denmark and Portugal.

AltoVerde is aiming to be the new kid on the block and wants to shake things up in an industry which it believes has gone from counter-culture to corporate.

Makwana told Cannabis Health: “It’s become a completely different scene. We know that there might be a view that us industry veterans aren’t ready to take on this new market but we just plan to get our heads down and get on with what we know best.

“We understand that there are big regulatory hurdles, but ultimately there is one goal: getting a good end product to consumers at a fair price.”

This team of ‘veterans’, some of whom have almost two decades experience in the industry, have been in the game since paraphernalia and souvenir seeds were the only way to make money out of cannabis in Europe.

Mitesh Makwana

But things are changing. The medical cannabis sector in Europe is forecast to explode over the next few years and companies set up and ready to go when liberalisation happens stand to make a fortune.

Makwana said: “The team and our roots set us apart from the rest of the industry.

“Many of the people involved with company have been active in this sector for several years, people who’ve spent years honing their expertise in cultivation, breeding, plantation management, clinical trials, chemistry and extraction.

“This plant has a lot of amazing properties and we’re passionate about unlocking them for consumers and patients.”

The company has already completed an initial funding round and is planning a private subscription to raise further capital in the near future.

Deals to begin two manufacturing operations in Europe, including a 10,000+ square metre cultivation plant in Macedonia, are nearing completion and the company has longer term ambitions to carry out its own clinical trials.

It’s early days but the company has set out a five-year growth plan and is targeting £13.1m in inward investment.

Makwana told Cannabis Health, AltoVerde, which is headquartered in the UK, will be involved from seed to distribution and will respond to change in the market and regulations.

He said: “We’re setting ourselves up to be able to adjust to the way market demands shift over the coming years.

“With our expertise we know we can satisfy demand from the medicinal and wellbeing markets.

“We’re positioning ourselves up to take advantage whichever way regulations go and however the market changes.

“With our experience we know we can change and adapt.”

 

Continue Reading

Trending